1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Tardive Dyskinesia (TD) Treatment Drugs Market
2.2. Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Drug, 2023 (US$ Million)
2.3. Global Tardive Dyskinesia (TD) Treatment Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Tardive Dyskinesia (TD) Treatment Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Tardive Dyskinesia (TD) Treatment Drugs Market Vendors
3.2. Strategies Adopted by Tardive Dyskinesia (TD) Treatment Drugs Market Vendors
3.3. Key Industry Strategies
4. Tardive Dyskinesia (TD) Treatment Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Tardive Dyskinesia (TD) Treatment Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Valbenazine
5.3.2. Deutetrabenazine
5.3.3. Other


6. North America Tardive Dyskinesia (TD) Treatment Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Tardive Dyskinesia (TD) Treatment Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

9. Latin America Tardive Dyskinesia (TD) Treatment Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Tardive Dyskinesia (TD) Treatment Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.Tardive Dyskinesia (TD) Treatment Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Tardive Dyskinesia (TD) Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Auspex Pharmaceuticals
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Neurocrine Biosciences, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Synchroneuron Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Teva Pharmaceutical Industries Ltd.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Other Notable Players
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives